遺伝子組換え凝固因子の市場規模、シェア、成長分析：製品タイプ別、血友病タイプ別、エンドユーザー別、地域別 - 産業予測 2025～2032年

遺伝子組換え凝固因子市場規模は2023年に140億米ドルと評価され、2024年の149億7,000万米ドルから2032年には255億2,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは6.9％で成長する見通しです。

遺伝子組換え凝固因子市場は、血漿ベースのソリューションに対する消費者の需要の増加とともに、血友病やその他の出血性疾患の罹患率の上昇によって成長を目の当たりにしています。第VIII因子、第IX因子、von Willebrand因子を含むこれらの因子は、組換えDNA技術によって製造され、感染症のトランスミッションのリスクが低く、より安全な代替品を提供しています。研究開発の活発化と承認製品の増加により、市場はさらに拡大しています。しかし、安価な代替血漿と比較して血友病治療にかかる費用が高いなどの課題も残っています。このような障害にもかかわらず、世界市場の見通しは依然として明るく、様々な地域で血友病の予防的治療法の採用が拡大していることがその要因となっています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

遺伝子組換え凝固因子市場規模：製品タイプ別& CAGR（2025-2032）

• 市場概要
• 組み換え因子VIII
• 組み換え因子IX
• フォン・ヴィレブランド因子

遺伝子組換え凝固因子市場規模：血友病タイプ別& CAGR（2025-2032）

• 市場概要
• 血友病A
• 血友病B

遺伝子組換え凝固因子市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 病院
• クリニック
• 調査機関

遺伝子組換え凝固因子市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Novo Nordisk（Denmark）
• Takeda Pharmaceutical Company Limited（Japan）
• Bayer AG（Germany）
• Pfizer Inc.（USA）
• Swedish Orphan Biovitrum AB（Sobi）（Sweden）
• CSL Behring（Australia）
• Roche Holding AG（Switzerland）
• Sanofi（France）
• Grifols, S.A.（Spain）
• Biogen Inc.（USA）
• Kedrion S.p.A.（Italy）
• Octapharma AG（Switzerland）
• Bio Products Laboratory Ltd.（UK）
• LFB S.A.（France）
• GC Pharma（South Korea）
• CSL Limited（Australia）
• Freeline Therapeutics（UK）
• Sangamo Therapeutics, Inc.（USA）

結論と提言

Recombinant Coagulation Factors Market size was valued at USD 14.0 billion in 2023 and is poised to grow from USD 14.97 billion in 2024 to USD 25.52 billion by 2032, growing at a CAGR of 6.9% during the forecast period (2025-2032).

The recombinant coagulation factors market is witnessing growth driven by the rising incidence of hemophilia and other bleeding disorders, alongside increasing consumer demand for plasma-derived solutions. These factors, including Factor VIII, Factor IX, and von Willebrand factor, are produced through recombinant DNA technology, offering safer alternatives with a lower risk of infectious agent transmission. The boost in research and development efforts, coupled with a growing number of product approvals, further enhances market expansion. However, challenges persist, including the high costs associated with hemophilia treatment compared to cheaper plasma alternatives. Despite these obstacles, the global market outlook remains positive, fueled by the expanding adoption of prophylactic treatments for hemophilia across various regions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Recombinant Coagulation Factors market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Recombinant Coagulation Factors Market Segments Analysis

Global Recombinant Coagulation Factors Market is segmented by Product Type, Hemophilia Type, End User and region. Based on Product Type, the market is segmented into Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor. Based on Hemophilia Type, the market is segmented into Hemophilia A and Hemophilia B. Based on End User, the market is segmented into Hospitals, Clinics and Research Organizations. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Recombinant Coagulation Factors Market

The Recombinant Coagulation Factors market has experienced a steady rise in research and development spending and funding within the pharmaceutical and biotechnology sectors. Leading market participants are dedicating substantial resources to the development of innovative, technologically advanced products, which enhances the adoption of Recombinant Coagulation Factors on a global scale, particularly in both developed and developing nations. This surge in utilization is a significant driver of growth for the global market. Moreover, the growing number of product approvals for new recombinant coagulation factors serves as a critical factor facilitating market expansion, further underlining the sector's dynamic progress and innovation.

Restraints in the Recombinant Coagulation Factors Market

The recombinant coagulation factors market faces significant restraints due to the high costs associated with hemophilia treatments when compared to lower-cost plasma coagulation options available in the market. Additionally, the presence of alternative treatment options further impacts the growth potential of the global recombinant coagulation factors market. These alternatives not only provide more affordable solutions for patients but also contribute to a competitive landscape that can hinder the adoption and demand for recombinant factors. As a result, these financial considerations and market alternatives present substantial challenges to the expansion of the recombinant coagulation factors market.

Market Trends of the Recombinant Coagulation Factors Market

The global recombinant coagulation factors market is witnessing significant growth, primarily fueled by the increasing prevalence of blood disorders, particularly haemophilia, and the corresponding rising adoption of advanced treatment options. Patients and healthcare providers are favoring recombinant coagulation factors due to their safety profile, lower risk of transmission of infectious agents, and improved efficacy over traditional plasma-derived factors. Additionally, ongoing advancements in biotechnological processes and the introduction of innovative therapies are further propelling market expansion. As awareness regarding these therapies rises and healthcare systems emphasize personalized medicine, the demand for recombinant coagulation factors is expected to surge, defining a robust market trend.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Recombinant Coagulation Factors Market Size by Product Type & CAGR (2025-2032)

• Market Overview
• Recombinant Factor VIII
• Recombinant Factor IX
• Von Willebrand Factor

Global Recombinant Coagulation Factors Market Size by Hemophilia Type & CAGR (2025-2032)

• Market Overview
• Hemophilia A
• Hemophilia B

Global Recombinant Coagulation Factors Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Research Organizations

Global Recombinant Coagulation Factors Market Size & CAGR (2025-2032)

• North America (Product Type, Hemophilia Type, End User)
  • US
  • Canada
• Europe (Product Type, Hemophilia Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Hemophilia Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Hemophilia Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Hemophilia Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Swedish Orphan Biovitrum AB (Sobi) (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Behring (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio Products Laboratory Ltd. (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LFB S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GC Pharma (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Freeline Therapeutics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations